Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04136444 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function
A Phase 1 study, sponsored by UCB Biopharma S.P.R.L..
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04136444 is a Phase 1 study that was terminated before completion, run by UCB Biopharma S.P.R.L.. The registered enrollment target is 12 participants.
The verdict
NCT04136444, a Phase 1 study, was terminated before completion, sponsored by UCB Biopharma S.P.R.L..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the plasma pharmacokinetic (PK), safety and tolerability of padsevonil (PSL) in hepatically impaired and non-hepatically impaired study participants.
Interventions
- DRUG Padsevonil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2020-05-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04136444
The ClinicalTrials.gov registry entry for NCT04136444 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma S.P.R.L., which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Padsevonil is the first listed.
NCT04136444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04136444 about?
NCT04136444 is a clinical study titled "A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function". The purpose of the study is to evaluate the plasma pharmacokinetic (PK), safety and tolerability of padsevonil (PSL) in hepatically impaired and non-hepatically impaired study participants.
What is the current status of trial NCT04136444?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-10-28. Estimated completion is 2020-05-22.
What interventions are being tested in trial NCT04136444?
The interventions under investigation include: Padsevonil (DRUG).
Who is sponsoring clinical trial NCT04136444?
This trial is sponsored by UCB Biopharma S.P.R.L., which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.